phrykt

Lexeo Therapeutics, Inc. (LXEO): who owns it and who trades it

As of Nov 16, 2026, LXEO insiders reported 17 open-market sales worth $752K and no purchases in the last 12 months, with 42% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard Nolan Townsend (CEO), with $538K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lexeo Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LXEO

142 funds and institutions reported LXEO shares worth $418M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 8.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Montanova Capital, LLC8.6%
Affinity Asset Advisors, LLC7.8%
BlackRock, Inc.7.7%
Ra Capital Management, L.P.6.7%
Frazier Life Sciences Management, L.P.6.5%
State Street Corp5.9%
Vestal Point Capital, LP5.8%
Paradigm Biocapital Advisors LP5.6%
Jupiter Topco LLC5.3%
Orbimed Advisors LLC5.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC6.38M8.62%$29.7M+411%
Affinity Asset Advisors, LLC5.81M7.84%$27M+15%
BlackRock, Inc.5.74M7.75%$26.7M+12%
Ra Capital Management, L.P.5.00M6.75%$23.3MNo change
Frazier Life Sciences Management, L.P.4.82M6.51%$22.5M+9%
State Street Corp4.35M5.88%$20.3M+22%
Vestal Point Capital, LP4.32M5.83%$20.1M-3%
Paradigm Biocapital Advisors LP4.18M5.64%$19.4M-32%
Jupiter Topco LLC3.95M5.34%$18.4M–
Orbimed Advisors LLC3.95M5.33%$18.4M+10%
Citadel Advisors LLC3.90M5.26%$18.1M+2%
Vanguard Capital Management LLC3.13M4.22%$14.6M+4%
Millennium Management LLC2.83M3.82%$13.2M+76%
Nantahala Capital Management, LLC2.60M3.51%$12.1M+117%
Woodline Partners LP2.50M3.38%$11.6M-9%
Balyasny Asset Management L.P.2.41M3.26%$11.2M+52%
Goldman Sachs Group Inc2.15M2.90%$10M+10%
683 Capital Management, LLC1.88M2.53%$8.7M+56%
Geode Capital Management, LLC1.75M2.36%$8.1M+15%
ADAR1 Capital Management, LLC1.57M2.11%$7.3M+7%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LXEO insiders reported $0 of open-market purchases and $752K of sales. 42% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$752K
17 trades, 7 people
Sales under a 10b5-1 plan
42%
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 19, 2026

Purchases and sales by month

$313K$313KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Louis Edward TamayoCFOSale4,117$4.91$20.2KForm 4
Aug 18, 2026Richard Nolan TownsendCEOSale3,345$4.95$16.6KForm 4
Aug 18, 2026Jose Manuel OteroChief Operating OfficerSale1,304$4.96$6.5KForm 4
Jul 1, 2026Louis Edward TamayoCFOSale4,641$4.49$20.8KForm 4
Jul 1, 2026Jose Manuel OteroChief Operating OfficerSale4,666$4.48$20.9KForm 4
Jul 1, 2026Narinder Pal BhallaChief Medical OfficerSale22,306$4.42$98.6KForm 4
Jul 1, 2026Richard Nolan TownsendCEOSale25,947$4.48$116KForm 4
May 18, 2026Jose Manuel OteroChief Operating OfficerSale1,302$5.07$6.6KForm 4
May 18, 2026Richard Nolan TownsendCEOSale3,342$5.06$16.9KForm 4
Apr 6, 2026Richard Nolan TownsendCEOSale plan55,000$5.69$313KForm 4
Feb 18, 2026Jose Manuel OteroChief Operating OfficerSale3,016$6.40$19.3KForm 4
Feb 18, 2026Richard Nolan TownsendCEOSale10,173$6.38$64.9KForm 4
Nov 18, 2025Jose Manuel OteroChief Operating OfficerSale721$9.27$6.7KForm 4
Nov 18, 2025Richard Nolan TownsendCEOSale1,127$9.27$10.4KForm 4
Nov 18, 2025Eric AdlerChief Medical OfficerSale615$9.27$5.7KForm 4
Nov 18, 2025Tai Sandi SeeChief Development OfficeSale386$9.27$3.6KForm 4
Nov 18, 2025Jenny RobertsonChief Legal OfficerSale549$9.27$5.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Richard Nolan TownsendChief Executive Officer, Director–$538KAug 18, 2026
Narinder Pal BhallaChief Medical Officer–$98.6KJul 1, 2026
Jose Manuel OteroChief Operating Officer–$60KAug 18, 2026
Louis Edward TamayoChief Financial Officer–$41.1KAug 18, 2026
Eric AdlerChief Medical Officer–$5.7KNov 18, 2025
Jenny RobertsonChief Legal Officer–$5.1KNov 18, 2025
Tai Sandi SeeChief Development Officer–$3.6KNov 18, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LXEO short interest

Very high short interest. 20.8% of LXEO shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 29%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.04M LXEO shares were sold short, 20.8% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 12.7 trading days (days to cover).

Shares short, % of all shares

20.8%May 15Oct 3026.2%

Days to cover

12.7May 15Oct 3037.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.04M20.77%-3%1.34M12.7
Oct 15, 202617.55M21.39%-9%1.75M10.0
Sep 30, 202619.25M23.46%-7%2.13M9.0
Sep 15, 202620.63M25.14%+1%616,77833.4
Aug 31, 202620.49M24.97%No change763,91026.8
Aug 14, 202620.48M24.96%+20%1.04M19.8
Jul 31, 202617.05M23.02%+4%1.01M16.9
Jul 15, 202616.35M22.07%+1%836,12319.6
Jun 30, 202616.13M21.77%+14%1.15M14.0
Jun 15, 202614.09M19.02%+2%748,94718.8
May 29, 202613.78M18.59%+4%793,54317.4
May 15, 202613.21M17.83%+1%702,02218.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lexeo Therapeutics company events

Lexeo Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 29, 2026.

  1. Sep 29, 2026DealCompletion of Acquisition or Disposal of Assets. Filing
  2. Sep 22, 2026AgreementLexeo Therapeutics, Inc. entered into an Agreement and Plan of Merger with Mantle Therapeutics Inc., Magma Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity… Filing
  3. Aug 12, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
  4. Jun 29, 2026VoteReported shareholder vote results. Filing
  5. Jun 15, 2026AnnouncementBelow is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Filing
  6. May 11, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
  7. Apr 30, 2026LeadershipDr. Laura Sepp-Lorenzino was appointed to the board of directors of Lexeo Therapeutics, Inc. Filing
  8. Mar 30, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
  9. Feb 5, 2026LeadershipLexeo Therapeutics, Inc. entered into a Transition and Consulting Agreement with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down from his role of Head of Research and will continue to provide certain advisory services to the Company until the earlier of (i) July 31… Filing
  10. Jan 27, 2026LeadershipLexeo Therapeutics, Inc. announced that the Board of Directors of the Company appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operating Officer of the Company, effective as of January 2, 2026. Filing
  11. Jan 12, 2026AnnouncementBelow is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lexeo Therapeutics financials

Famous investors that hold LXEO

5 of the 50 well-known investors we track reported holding LXEO in their latest 13F filing. The largest position is Ken Griffin's, worth $14.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20264.24M$14.3M0.0%+9%
Israel Englander · Millennium ManagementQ3 20263.78M$12.8M0.0%+33%
Steve Cohen · Point72 Asset ManagementQ3 2026447,197$1.5M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026371,522$1.3M0.0%+48%
Ken Fisher · Fisher Asset ManagementQ3 2026114,322$386K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 16 filings named LXEO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A7.2%
Nov 16, 2026Vestal Point Capital, LP13G/A6.3%
Nov 16, 2026OrbiMed Advisors LLC13G/A3.9%
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A0.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A7.2%
Nov 16, 2026OrbiMed Advisors LLC13G/A3.9%
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A0.0%
Nov 16, 2026Vestal Point Capital, LP13G/A6.3%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A9.8%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A9.8%
Nov 10, 2026STATE STREET CORPORATION13G4.4%
Nov 10, 2026STATE STREET CORPORATION13G4.4%
Oct 13, 2026JPMORGAN CHASE & CO.13G5.5%
Oct 13, 2026JPMORGAN CHASE & CO.13G5.5%

Questions about Lexeo Therapeutics, Inc. (LXEO) stock

Who owns the most LXEO stock?

The largest reported owner of Lexeo Therapeutics, Inc. (LXEO) is Montanova Capital, LLC, with 8.6% of the company. In total, 142 funds and institutions reported holding LXEO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are LXEO insiders buying or selling?

In the last 12 months, LXEO insiders reported no open-market purchases and 17 sales worth $752K. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in LXEO?

As of Oct 30, 2026, 17.04M LXEO shares were sold short, 20.8% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 12.7 trading days (days to cover). See the history.

Which famous investors hold LXEO?

5 of the 50 well-known investors we track reported LXEO in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $14.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.